{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T14:00:21Z","timestamp":1790258421432,"version":"4.1.0"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T00:00:00Z","timestamp":1786492800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T00:00:00Z","timestamp":1786492800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Drug Investig"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1007\/s40261-026-01587-3","type":"journal-article","created":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T10:26:56Z","timestamp":1786530416000},"page":"1105-1120","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and Safety of Ustekinumab Biosimilars in the Treatment of Moderate-to-Severe Plaque Psoriasis: A Systematic Review and Meta-analysis"],"prefix":"10.1007","volume":"46","author":[{"given":"Mohsin","family":"Rashid","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-3020-9394","authenticated-orcid":false,"given":"Awon","family":"Muhammad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eeraj","family":"Saeed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali Akram","family":"Qureshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad Maheer","family":"Mubashir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad","family":"Waqas bin Waheed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Abdullah","family":"Yasin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad","family":"Abdullah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahsan","family":"Rashid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zainab","family":"Zubair","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,12]]},"reference":[{"key":"1587_CR1","doi-asserted-by":"publisher","first-page":"170","DOI":"10.7861\/clinmed.2021-0257","volume":"21","author":"A Raharja","year":"2021","unstructured":"Raharja A, Mahil SK, Barker JN. Psoriasis: a brief overview. Clin Med. 2021;21:170\u20133. https:\/\/doi.org\/10.7861\/clinmed.2021-0257.","journal-title":"Clin Med"},{"key":"1587_CR2","doi-asserted-by":"publisher","DOI":"10.4088\/PCC.14m01629","author":"AR Khawaja","year":"2015","unstructured":"Khawaja AR, Bokhari SM, Tariq R, Atif S, Muhammad H, Faisal Q, et al. Disease severity, quality of life, and psychiatric morbidity in patients with psoriasis with reference to sociodemographic, lifestyle, and clinical variables: a prospective, cross-sectional study from Lahore, Pakistan. Prim Care Companion CNS Disord. 2015. https:\/\/doi.org\/10.4088\/PCC.14m01629.","journal-title":"Prim Care Companion CNS Disord."},{"key":"1587_CR3","doi-asserted-by":"publisher","first-page":"175","DOI":"10.2147\/PTT.S519420","volume":"15","author":"M Ponikowska","year":"2025","unstructured":"Ponikowska M, Vellone E, Czapla M, Uchmanowicz I. Challenges psoriasis and its impact on quality of life: challenges in treatment and management. Psoriasis (Auckl). 2025;15:175\u201383. https:\/\/doi.org\/10.2147\/PTT.S519420.","journal-title":"Psoriasis (Auckl)."},{"key":"1587_CR4","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1001\/jamadermatol.2021.2007","volume":"157","author":"AW Armstrong","year":"2021","unstructured":"Armstrong AW, Mehta MD, Schupp CW, Gondo GC, Bell SJ, Griffiths CEM. Psoriasis prevalence in adults in the United States. JAMA Dermatol. 2021;157:940\u20136. https:\/\/doi.org\/10.1001\/jamadermatol.2021.2007.","journal-title":"JAMA Dermatol"},{"key":"1587_CR5","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1111\/jdv.13854","volume":"31","author":"IM Michalek","year":"2017","unstructured":"Michalek IM, Loring B, John SM. A systematic review of worldwide epidemiology of psoriasis. J Eur Acad Dermatol Venereol. 2017;31:205\u201312. https:\/\/doi.org\/10.1111\/jdv.13854.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1587_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1365-2249.2004.02310.x","volume":"135","author":"JE Gudjonsson","year":"2004","unstructured":"Gudjonsson JE, Johnston A, Sigmundsdottir H, Valdimarsson H. Immunopathogenic mechanisms in psoriasis. Clin Exp Immunol. 2004;135:1\u20138. https:\/\/doi.org\/10.1111\/j.1365-2249.2004.02310.x.","journal-title":"Clin Exp Immunol"},{"key":"1587_CR7","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1111\/ced.12390","volume":"39","author":"Y Meng","year":"2014","unstructured":"Meng Y, Dongmei L, Yanbin P, Jinju F, Meile T, Binzhu L, et al. Systematic review and meta\u2010analysis of ustekinumab for moderate to severe psoriasis. Clin Exp Dermatol. 2014;39:696\u2013707. https:\/\/doi.org\/10.1111\/ced.12390.","journal-title":"Clin Exp Dermatol"},{"key":"1587_CR8","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1016\/j.jaad.2018.11.057","volume":"80","author":"A Menter","year":"2019","unstructured":"Menter A, Strober BE, Kaplan DH, Kivelevitch R, Prater EF, Stoff B, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. J Am Acad Dermatol. 2019;80:1029\u201372. https:\/\/doi.org\/10.1016\/j.jaad.2018.11.057.","journal-title":"J Am Acad Dermatol"},{"key":"1587_CR9","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1056\/NEJMoa0810652","volume":"362","author":"CEM Griffiths","year":"2010","unstructured":"Griffiths CEM, Strober BE, Van De Kerkhof P, Ho V, Fidelus-Gort R, Yeilding N, et al. Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis. N Engl J Med. 2010;362:118\u201328. https:\/\/doi.org\/10.1056\/NEJMoa0810652.","journal-title":"N Engl J Med"},{"key":"1587_CR10","doi-asserted-by":"publisher","DOI":"10.7573\/dic.212266","volume":"3","author":"J Cheng","year":"2014","unstructured":"Cheng J, Feldman SR. The cost of biologics for psoriasis is increasing. Drugs Context. 2014;3:212266. https:\/\/doi.org\/10.7573\/dic.212266.","journal-title":"Drugs Context."},{"key":"1587_CR11","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1080\/09546634.2018.1466022","volume":"29","author":"JJ Wu","year":"2018","unstructured":"Wu JJ, Feldman SR, Rastogi S, Menges B, Lingohr-Smith M, Lin J. Comparison of the cost-effectiveness of biologic drugs used for moderate-to-severe psoriasis treatment in the United States. J Dermatolog Treat. 2018;29:769\u201374. https:\/\/doi.org\/10.1080\/09546634.2018.1466022.","journal-title":"J Dermatolog Treat"},{"key":"1587_CR12","unstructured":"Singh SC, Bagnato KM. The economic implications of biosimilars. Am J Manag Care. 2015;21(16 Suppl):s331\u201340. https:\/\/www.ajmc.com\/view\/ace0039_dec15_biosimilars_singhbagnato. Accessed 25 Sept 2025."},{"key":"1587_CR13","unstructured":"Stelara patent deal puts J&J back on path to $57 billion 2025 revenue forecast | Reuters [Internet]. 2023. https:\/\/www.reuters.com\/business\/healthcare-pharmaceuticals\/stelara-patent-deal-puts-jj-back-path-57-bln-2025-revenue-forecast-2023-06-05\/.\u00a0Accessed 25 Sept 2025."},{"key":"1587_CR14","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1080\/14712598.2019.1636963","volume":"19","author":"L Puig","year":"2019","unstructured":"Puig L, L\u00f3pez-Ferrer A. Biosimilars for the treatment of psoriasis. Expert Opin Biol Ther. 2019;19:993\u20131000. https:\/\/doi.org\/10.1080\/14712598.2019.1636963.","journal-title":"Expert Opin Biol Ther"},{"key":"1587_CR15","doi-asserted-by":"crossref","unstructured":"Mulcahy AW, Hlavka JP, Case SR. Biosimilar cost savings in the United States: initial experience and future potential. Rand Health Q. 2018;7:3. https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC6075809\/.","DOI":"10.7249\/rhq-07-04-03"},{"key":"1587_CR16","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1002\/art.41946","volume":"74","author":"YS Rosenthal","year":"2022","unstructured":"Rosenthal YS, Schwartz N, Sagy I, Pavlovsky L. Incidence of psoriatic arthritis among patients receiving biologic treatments for psoriasis: a nested case\u2013control study. Arthritis Rheumatol. 2022;74:237\u201343. https:\/\/doi.org\/10.1002\/art.41946.","journal-title":"Arthritis Rheumatol"},{"key":"1587_CR17","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1080\/14712598.2023.2235263","volume":"23","author":"SR Feldman","year":"2023","unstructured":"Feldman SR, Reznichenko N, Berti F, Duijzings P, Ruffieux R, Otto H, et al. Randomized, double-blind, multicenter study to evaluate efficacy, safety, tolerability, and immunogenicity between AVT04 and the reference product ustekinumab in patients with moderate-to-severe chronic plaque psoriasis. Expert Opin Biol Ther. 2023;23:759\u201371. https:\/\/doi.org\/10.1080\/14712598.2023.2235263.","journal-title":"Expert Opin Biol Ther"},{"key":"1587_CR18","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2020","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2020;372:n71. https:\/\/doi.org\/10.1136\/bmj.n71.","journal-title":"BMJ"},{"key":"1587_CR19","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1080\/02763869.2019.1588072","volume":"38","author":"JH Schiavo","year":"2019","unstructured":"Schiavo JH. PROSPERO: an international register of systematic review protocols. Med Ref Serv Q. 2019;38:171\u201380. https:\/\/doi.org\/10.1080\/02763869.2019.1588072.","journal-title":"Med Ref Serv Q"},{"key":"1587_CR20","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898","volume":"366","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:l4898. https:\/\/doi.org\/10.1136\/bmj.l4898.","journal-title":"BMJ"},{"key":"1587_CR21","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/j.jclinepi.2010.07.015","volume":"64","author":"H Balshem","year":"2011","unstructured":"Balshem H, Helfand M, Sch\u00fcnemann HJ, Oxman AD, Kunz R, Brozek J, et al. GRADE guidelines: 3. Rating the quality of evidence. J Clin Epidemiol. 2011;64:401\u20136. https:\/\/doi.org\/10.1016\/j.jclinepi.2010.07.015.","journal-title":"J Clin Epidemiol"},{"key":"1587_CR22","unstructured":"McMaster University and Evidence Prime. GRADEpro GDT: GRADEpro Guideline Development Tool. 2023. https:\/\/gradepro.org."},{"key":"1587_CR23","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1016\/j.jaad.2004.04.012","volume":"51","author":"RG Langley","year":"2004","unstructured":"Langley RG, Ellis CN. Evaluating psoriasis with Psoriasis Area and Severity Index, Psoriasis Global Assessment, and Lattice System Physician\u2019s Global Assessment. J Am Acad Dermatol. 2004;51:563\u20139. https:\/\/doi.org\/10.1016\/j.jaad.2004.04.012.","journal-title":"J Am Acad Dermatol"},{"key":"1587_CR24","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1111\/j.1365-2230.1994.tb01167.x","volume":"19","author":"AY Finlay","year":"1994","unstructured":"Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI)\u2014a simple practical measure for routine clinical use. Clin Exp Dermatol. 1994;19:210\u20136. https:\/\/doi.org\/10.1111\/j.1365-2230.1994.tb01167.x.","journal-title":"Clin Exp Dermatol"},{"key":"1587_CR25","unstructured":"The Cochrane Collaboration. Review Manager 5.4 (RevMan 5.4). Copenhagen; 2020."},{"key":"1587_CR26","volume-title":"Cochrane handbook for systematic reviews of interventions","year":"2019","unstructured":"Higgins JPT, Thomas J, Chandler J, et al editors. Cochrane handbook for systematic reviews of interventions. 2nd edition. Hoboken: Wiley-Blackwell; 2019.","edition":"2nd edition"},{"key":"1587_CR27","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1097\/XEB.0000000000000141","volume":"16","author":"L Furuya-Kanamori","year":"2018","unstructured":"Furuya-Kanamori L, Barendregt JJ, Doi SAR. A new improved graphical and quantitative method for detecting bias in meta-analysis. Int J Evid Based Healthc. 2018;16:195\u2013203. https:\/\/doi.org\/10.1097\/XEB.0000000000000141.","journal-title":"Int J Evid Based Healthc"},{"key":"1587_CR28","doi-asserted-by":"publisher","DOI":"10.1111\/jep.14138","volume":"31","author":"I Elmakaty","year":"2025","unstructured":"Elmakaty I. Mastering meta-analysis in Microsoft Excel with MetaXL add-in: a comprehensive tutorial and guide to meta-analysis. J Eval Clin Pract. 2025;31:e14138. https:\/\/doi.org\/10.1111\/jep.14138.","journal-title":"J Eval Clin Pract"},{"key":"1587_CR29","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1093\/bjd\/ljae402","volume":"192","author":"A Blauvelt","year":"2025","unstructured":"Blauvelt A, Papp K, Trivedi M, Barragan C, Chow V, Mytych DT, et al. Efficacy and safety of the ustekinumab biosimilar ABP 654 in patients with moderate-to-severe plaque psoriasis: a randomized double-blinded active-controlled comparative clinical study over 52 weeks. Br J Dermatol. 2025;192:826\u201336. https:\/\/doi.org\/10.1093\/bjd\/ljae402.","journal-title":"Br J Dermatol"},{"key":"1587_CR30","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1016\/j.jaad.2024.04.045","volume":"91","author":"SR Feldman","year":"2024","unstructured":"Feldman SR, Narbutt J, Girolomoni G, Brzezicki J, Reznichenko N, Zegad\u0142o-Mylik MA, et al. A randomized, double-blind, phase III study assessing clinical similarity of SB17 (proposed ustekinumab biosimilar) to reference ustekinumab in subjects with moderate-to-severe plaque psoriasis. J Am Acad Dermatol. 2024;91:440\u20137. https:\/\/doi.org\/10.1016\/j.jaad.2024.04.045.","journal-title":"J Am Acad Dermatol"},{"key":"1587_CR31","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2024.2436607","volume":"35","author":"SR Feldman","year":"2024","unstructured":"Feldman SR, Narbutt J, Girolomoni G, Brzezicki J, Reznichenko N, Zegad\u0142o-Mylik MA, et al. Biosimilar SB17 versus reference ustekinumab in moderate to severe plaque psoriasis after switching: phase 3 study results up to week 52. J Dermatolog Treat. 2024;35:2436607. https:\/\/doi.org\/10.1080\/09546634.2024.2436607.","journal-title":"J Dermatolog Treat"},{"key":"1587_CR32","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1016\/j.jaad.2024.10.104","volume":"92","author":"X Man","year":"2025","unstructured":"Man X, Zaharieva K, Pulka G, \u017bebrowska A, Deng Y, Mekokishvili L, et al. A randomized phase III study to compare efficacy and safety of BAT2206 (proposed ustekinumab biosimilar) with reference ustekinumab in patients with moderate to severe plaque psoriasis. J Am Acad Dermatol. 2025;92:724\u201331. https:\/\/doi.org\/10.1016\/j.jaad.2024.10.104.","journal-title":"J Am Acad Dermatol"},{"key":"1587_CR33","unstructured":"Dong-A ST Co., Ltd. A randomized, double-blind, multicentric, parallel group therapeutic equivalence study comparing efficacy, safety and immunogenicity of subcutaneous DMB-3115 and Stelara\u00ae in patients with moderate to severe chronic plaque psoriasis [Internet]. clinicaltrials.gov; 2024. Report No.: NCT04785326. https:\/\/clinicaltrials.gov\/study\/NCT04785326.\u00a0Accessed 12 Oct 2025."},{"key":"1587_CR34","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1007\/s40259-023-00630-5","volume":"38","author":"KA Papp","year":"2024","unstructured":"Papp KA, Lebwohl MG, Tha\u00e7i D, Jaworski J, Kwiek B, Trefler J, et al. Efficacy and safety of candidate biosimilar CT-P43 versus originator ustekinumab in moderate to severe plaque psoriasis: 28-week results of a randomised, active-controlled, double-blind, phase III study. BioDrugs. 2024;38:121\u201331. https:\/\/doi.org\/10.1007\/s40259-023-00630-5.","journal-title":"BioDrugs"},{"key":"1587_CR35","doi-asserted-by":"publisher","first-page":"2135","DOI":"10.1007\/s12325-025-03138-2","volume":"42","author":"K Papp","year":"2025","unstructured":"Papp K, Balser S, Nopora K, Rewerski P, Freudensprung B, Trieb M. A randomised, double-blind trial to compare the efficacy, safety, and immunogenicity of the biosimilar ustekinumab FYB202 with reference ustekinumab in patients with moderate-to-severe plaque psoriasis. Adv Ther. 2025;42:2135\u201349. https:\/\/doi.org\/10.1007\/s12325-025-03138-2.","journal-title":"Adv Ther"},{"key":"1587_CR36","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1080\/14712598.2025.2538608","volume":"25","author":"JC Szepietowski","year":"2025","unstructured":"Szepietowski JC, Reich A, Feldman SR, Pulka G, Mekokishvili L, Tsiskarishvili N, et al. Efficacy and safety of the ustekinumab biosimilar, Bmab 1200, versus reference ustekinumab in moderate-to-severe plaque psoriasis: 28\u2011week results of the randomized, double-blind, phase 3 STELLAR-2 study. Expert Opin Biol Ther. 2025;25:913\u201324. https:\/\/doi.org\/10.1080\/14712598.2025.2538608.","journal-title":"Expert Opin Biol Ther"},{"key":"1587_CR37","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.jaad.2025.03.018","volume":"93","author":"L Xia","year":"2025","unstructured":"Xia L, Miao G, Yang X, Li Y, Liang Y, Li Y, et al. Efficacy and safety of SYSA1902 versus reference ustekinumab in moderate-to-severe plaque psoriasis: a multicenter, randomized, phase III study. J Am Acad Dermatol. 2025;93:115\u201323. https:\/\/doi.org\/10.1016\/j.jaad.2025.03.018.","journal-title":"J Am Acad Dermatol"},{"key":"1587_CR38","unstructured":"Christl L. FDA\u2019s overview of the regulatory guidance for the development and approval of biosimilar products in the US [Internet]. U.S. Food and Drug Administration; 2023. https:\/\/www.fda.gov\/files\/drugs\/published\/FDA%E2%80%99s-Overview-of-the-Regulatory-Guidance-for-the-Development-and-Approval-of-Biosimilar-Products-in-the-US.pdf.\u00a0Accessed: 12 Oct 2025."},{"key":"1587_CR39","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2023.2249145","volume":"34","author":"C Li","year":"2023","unstructured":"Li C, Sunhe Y, Zhou H, Dong W. Efficacy and safety evaluations of adalimumab biosimilars in the treatment of psoriasis. J Dermatolog Treat. 2023;34:2249145. https:\/\/doi.org\/10.1080\/09546634.2023.2249145.","journal-title":"J Dermatolog Treat"},{"key":"1587_CR40","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1016\/j.survophthal.2025.11.007","volume":"71","author":"M Rashid","year":"2026","unstructured":"Rashid M, Azeem S, Shahid IF, Ali MKB, Shahid F, Fatima A, et al. Efficacy and safety of aflibercept biosimilars compared to reference aflibercept for retinal diseases: a systematic review and meta-analysis. Surv Ophthalmol. 2026;71:780\u201392. https:\/\/doi.org\/10.1016\/j.survophthal.2025.11.007.","journal-title":"Surv Ophthalmol"},{"key":"1587_CR41","doi-asserted-by":"publisher","first-page":"407","DOI":"10.3390\/biologics4040025","volume":"4","author":"E Carmona-Rocha","year":"2024","unstructured":"Carmona-Rocha E, Puig L. Ustekinumab biosimilars. Biologics. 2024;4:407\u201322. https:\/\/doi.org\/10.3390\/biologics4040025.","journal-title":"Biologics"},{"key":"1587_CR42","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1111\/bjd.16927","volume":"179","author":"F Rencz","year":"2018","unstructured":"Rencz F, Gul\u00e1csi L, P\u00e9ntek M, Po\u00f3r AK, S\u00e1rdy M, Holl\u00f3 P, et al. Proposal of a new scoring formula for the Dermatology Life Quality Index in psoriasis. Br J Dermatol. 2018;179:1102\u20138. https:\/\/doi.org\/10.1111\/bjd.16927.","journal-title":"Br J Dermatol"},{"key":"1587_CR43","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1111\/j.1468-3083.2009.03562.x","volume":"24","author":"E Puzenat","year":"2010","unstructured":"Puzenat E, Bronsard V, Prey S, Gourraud P-A, Aractingi S, Bagot M, et al. What are the best outcome measures for assessing plaque psoriasis severity? A systematic review of the literature. J Eur Acad Dermatol Venereol. 2010;24:10\u20136. https:\/\/doi.org\/10.1111\/j.1468-3083.2009.03562.x.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1587_CR44","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/j.jaad.2011.01.022","volume":"66","author":"A Robinson","year":"2012","unstructured":"Robinson A, Kardos M, Kimball AB. Physician Global Assessment (PGA) and Psoriasis Area and Severity Index (PASI): why do both? A systematic analysis of randomized controlled trials of biologic agents for moderate to severe plaque psoriasis. J Am Acad Dermatol. 2012;66:369\u201375. https:\/\/doi.org\/10.1016\/j.jaad.2011.01.022.","journal-title":"J Am Acad Dermatol"},{"key":"1587_CR45","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1111\/bjd.12214","volume":"168","author":"KA Papp","year":"2013","unstructured":"Papp KA, Griffiths CEM, Gordon K, Lebwohl M, Szapary PO, Wasfi Y, et al. Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5 years of follow-up. Br J Dermatol. 2013;168:844\u201354. https:\/\/doi.org\/10.1111\/bjd.12214.","journal-title":"Br J Dermatol"},{"key":"1587_CR46","doi-asserted-by":"publisher","DOI":"10.1016\/j.soncn.2019.08.006","volume":"35","author":"V Bayer","year":"2019","unstructured":"Bayer V. An overview of monoclonal antibodies. Semin Oncol Nurs. 2019;35:150927. https:\/\/doi.org\/10.1016\/j.soncn.2019.08.006.","journal-title":"Semin Oncol Nurs"},{"key":"1587_CR47","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.01951","volume":"11","author":"A Vaisman-Mentesh","year":"2020","unstructured":"Vaisman-Mentesh A, Gutierrez-Gonzalez M, DeKosky BJ, Wine Y. The molecular mechanisms that underlie the immune biology of anti-drug antibody formation following treatment with monoclonal antibodies. Front Immunol. 2020;11:1951. https:\/\/doi.org\/10.3389\/fimmu.2020.01951.","journal-title":"Front Immunol"},{"key":"1587_CR48","unstructured":"European Medicines Agency. Guideline on Immunogenicity assessment of therapeutic proteins. 2017. https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-immunogenicity-assessment-therapeutic-proteins-revision-1_en.pdf. Accessed 12 Oct 2025."},{"key":"1587_CR49","doi-asserted-by":"publisher","first-page":"1881","DOI":"10.1007\/s40265-021-01601-2","volume":"81","author":"P Kurki","year":"2021","unstructured":"Kurki P, Barry S, Bourges I, Tsantili P, Wolff-Holz E. Safety, immunogenicity and interchangeability of biosimilar monoclonal antibodies and fusion proteins: a regulatory perspective. Drugs. 2021;81:1881\u201396. https:\/\/doi.org\/10.1007\/s40265-021-01601-2.","journal-title":"Drugs"},{"key":"1587_CR50","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2021-001637","volume":"7","author":"JS Smolen","year":"2021","unstructured":"Smolen JS, Caporali R, Doerner T, Fautrel B, Benedetti F, Pieper B, et al. Treatment journey in rheumatoid arthritis with biosimilars: from better access to good disease control through cost savings and prevention of nocebo effects. RMD Open. 2021;7:e001637. https:\/\/doi.org\/10.1136\/rmdopen-2021-001637.","journal-title":"RMD Open"}],"container-title":["Clinical Drug Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-026-01587-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40261-026-01587-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-026-01587-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T13:13:55Z","timestamp":1790255635000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40261-026-01587-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,12]]},"references-count":50,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["1587"],"URL":"https:\/\/doi.org\/10.1007\/s40261-026-01587-3","relation":{},"ISSN":["1173-2563","1179-1918"],"issn-type":[{"value":"1173-2563","type":"print"},{"value":"1179-1918","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,12]]},"assertion":[{"value":"18 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing financial interests or personal relationships that could have influenced the findings or conclusions of this review.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Ethics Approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Consent to Participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":4,"name":"Ethics","label":"Consent for Publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":5,"name":"Ethics","label":"Code Availability","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All data generated or analysed during this study are included in this published article and its supplementary information files\n                      .","order":6,"name":"Ethics","label":"Availability of Data and Material","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Mohsin Rashid and Awon Muhammad contributed equally to the development of this manuscript and are joint first authors. Both authors contributed to the conception and design of the study, development of the protocol, interpretation of data, and drafting of the manuscript. Eeraj Saeed and Ahsan Rashid conducted the literature search, study screening, and data extraction. Ali Akram Qureshi, Mohammad Maheer Mubashir, and Mohammad Waqas bin Waheed contributed to data analysis, statistical interpretation, and preparation of figures and tables. Muhammad Abdullah Yasin and Muhammad Abdullah performed risk-of-bias assessment, quality appraisal, and manuscript revision for important intellectual content. Zainab Zubair contributed to data verification, methodological oversight, and critical revision of the manuscript. All authors read and approved the final version and agree to be accountable for the work.","order":7,"name":"Ethics","label":"Author Contributions","group":{"name":"EthicsHeading","label":"Declarations"}}]}}